Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts maintain a “Hold” consensus on Amgen, with 15 hold, 11 buy, 3 sell and 1 strong-buy ratings; the average 12-month price target is $381.32.
• Amgen’s Phase 3 OASIZ 301 trial for dazodalibep met its primary endpoint in moderate-to-severe Sjögren’s disease, strengthening the drug’s pipeline prospects, though the company must await results from another study before filing for regulatory approval.
• The company recently exceeded quarterly expectations, reporting $6.29 in EPS and $10.05 billion in revenue, while maintaining 2026 EPS guidance of $22.30–$23.50 and paying a quarterly dividend of $2.52 per share.

Shares of Amgen Inc. (NASDAQ:AMGN - Get Free Report) have been given a consensus rating of "Hold" by the thirty ratings firms that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $381.3214.

AMGN has been the topic of a number of recent analyst reports. Bank of America lifted their target price on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Barclays raised their price target on shares of Amgen from $360.00 to $380.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th. Weiss Ratings raised shares of Amgen from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, August 6th. Finally, Wells Fargo & Company lifted their price target on shares of Amgen from $400.00 to $435.00 and gave the company an "equal weight" rating in a report on Friday, September 4th.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that its Phase 3 OASIZ 301 trial met its primary endpoint: dazodalibep significantly reduced systemic disease activity in adults with moderate-to-severe Sjögren’s disease. The result strengthens the drug’s potential as a new treatment option for the autoimmune condition and was the primary catalyst behind the stock’s advance. Amgen's autoimmune drug succeeds in late-stage trial
• Positive Sentiment: The trial win improves the commercial outlook for dazodalibep, which could potentially become a first-in-class or otherwise differentiated therapy for Sjögren’s disease. Analysts and investors are treating the data as a meaningful pipeline de-risking event. Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
• Neutral Sentiment: Despite the positive OASIZ 301 result, Amgen said it must await data from another study before submitting a regulatory filing. That means the treatment remains subject to additional clinical and regulatory milestones, delaying any potential revenue contribution. Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease
• Neutral Sentiment: Amgen’s expanded global partnership with Veeva for a Vault CRM rollout reinforces the company’s commercial infrastructure, but the announcement is unlikely to materially change near-term earnings expectations. Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
• Negative Sentiment: Erste Group Bank slightly lowered its FY2027 EPS forecast for Amgen to $24.36 from $24.43. The small revision suggests limited pressure on forward estimates, although it remains above the current-year consensus estimate of $22.94. Amgen analyst earnings estimate update

Amgen Stock Performance

NASDAQ AMGN opened at $410.24 on Wednesday. The firm's 50 day simple moving average is $403.52 and its 200 day simple moving average is $368.01. The firm has a market capitalization of $221.79 billion, a price-to-earnings ratio of 25.50, a P/E/G ratio of 2.84 and a beta of 0.43. Amgen has a 1 year low of $269.77 and a 1 year high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the company posted $6.02 EPS. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 over the last quarter. Company insiders own 0.85% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMGN. Rational Advisors Inc. grew its position in shares of Amgen by 13.7% during the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company's stock valued at $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC lifted its holdings in Amgen by 2.0% in the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company's stock worth $461,000 after acquiring an additional 25 shares during the last quarter. Legacy Financial Advisors Inc. boosted its stake in Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company's stock valued at $1,234,000 after acquiring an additional 26 shares during the period. Roman Butler Fullerton & Co. boosted its stake in Amgen by 1.4% in the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company's stock valued at $705,000 after acquiring an additional 27 shares during the period. Finally, TAGStone Capital Inc. grew its holdings in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock valued at $1,351,000 after purchasing an additional 28 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen's medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.